| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2014PLoSO...9j9115F |
| P356 | DOI | 10.1371/JOURNAL.PONE.0109115 |
| P932 | PMC publication ID | 4183544 |
| P698 | PubMed publication ID | 25275313 |
| P5875 | ResearchGate publication ID | 266569465 |
| P50 | author | Martin Storr | Q112528022 |
| Donna-Marie McCafferty | Q117258932 | ||
| Jakub Fichna | Q22115026 | ||
| Alexandros Makriyannis | Q28480394 | ||
| Keith A. Sharkey | Q38328653 | ||
| P2093 | author name string | Ganesh A Thakur | |
| Ritesh Tichkule | |||
| Misha Bawa | |||
| P2860 | cites work | Inflammatory Bowel Disease | Q22248115 |
| Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations | Q24309438 | ||
| Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide-treated rats | Q28271665 | ||
| Cannabinoids and the gut: new developments and emerging concepts | Q28271862 | ||
| Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation | Q28361058 | ||
| Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats | Q28568772 | ||
| Neutrophils and immunity: challenges and opportunities | Q29617616 | ||
| Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation. | Q30373403 | ||
| Mass spectrometry-based proteomics of human cannabinoid receptor 2: covalent cysteine 6.47(257)-ligand interaction affording megagonist receptor activation | Q30406301 | ||
| Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a peripherally restricted cannabinoid CB1/CB2 receptor agonist, inhibits gastrointestinal motility but has no effect on experimental colitis in mice | Q34122251 | ||
| Anandamide receptors | Q34132168 | ||
| Salvinorin A has antiinflammatory and antinociceptive effects in experimental models of colitis in mice mediated by KOR and CB1 receptors | Q34219916 | ||
| Management of active Crohn disease | Q34345967 | ||
| Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing | Q34440704 | ||
| Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. | Q34602111 | ||
| Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration | Q34650725 | ||
| Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2. | Q34707322 | ||
| Review article: the aetiopathogenesis of inflammatory bowel disease--immunology and repair mechanisms | Q35880361 | ||
| Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation | Q36854897 | ||
| The endogenous cannabinoid system protects against colonic inflammation | Q37370275 | ||
| Plasticity of enteric nerve functions in the inflamed and postinflamed gut. | Q37445127 | ||
| Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids | Q39124297 | ||
| The cannabinoid agonist WIN 55,212-2 inhibits TNF-alpha-induced neutrophil transmigration across ECV304 cells | Q40240416 | ||
| Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation | Q40757331 | ||
| Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system | Q41129837 | ||
| Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis | Q41155333 | ||
| delta 9-Tetrahydrocannabinol modulates antigen processing by macrophages | Q41337353 | ||
| Cannabinoid-receptor expression in human leukocytes | Q41553271 | ||
| Phagocytic and macropinocytic activity in MARCKS-deficient macrophages and fibroblasts | Q42474836 | ||
| Localization of cannabinoid receptor mRNA in rat brain | Q42510202 | ||
| Lipopolysaccharide: a p38 MAPK-dependent disrupter of neutrophil chemotaxis | Q43595416 | ||
| Delta-9-tetrahydrocannabinol inhibits macrophage protein expression in response to bacterial immunomodulators | Q43781437 | ||
| Localisation of cannabinoid CB(1) receptor immunoreactivity in the guinea pig and rat myenteric plexus | Q44062680 | ||
| delta-9-Tetrahydrocannabinol inhibits cell contact-dependent cytotoxicity of Bacillus Calmétte-Guérin-activated macrophages | Q45043331 | ||
| Targeting endocannabinoid degradation protects against experimental colitis in mice: involvement of CB1 and CB2 receptors | Q46584481 | ||
| Tetrahydrocannabinol treatment suppresses growth restriction of Legionella pneumophila in murine macrophage cultures | Q46595835 | ||
| (-)-7'-Isothiocyanato-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor | Q46699167 | ||
| Anadamide, an endogenous cannabinoid receptor agonist inhibits lymphocyte proliferation and induces apoptosis | Q46850762 | ||
| Effects of peripheral cannabinoid receptor ligands on motility and polarization in neutrophil-like HL60 cells and human neutrophils | Q46973009 | ||
| Effects of cannabinoids and cocaine on the mitogen-induced transformations of lymphocytes of human and mouse origins | Q51701124 | ||
| Marijuana components suppress induction and cytolytic function of murine cytotoxic T cells in vitro and in vivo | Q55049959 | ||
| Neural patterns in inflammatory bowel disease: an immunohistochemical survey | Q68566654 | ||
| Alveolar macrophages. Structural and functional differences between nonsmokers and smokers of marijuana and tobacco | Q68627545 | ||
| Tetrahydrocannabinol-induced suppression of macrophage spreading and phagocytic activity in vitro | Q70140462 | ||
| Localization of CB1-cannabinoid receptor immunoreactivity in the porcine enteric nervous system | Q73193706 | ||
| The immune response of peritoneal macrophages due to exposure to inorganic lead in the house mouse Mus musculus | Q81497067 | ||
| Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium | Q83019190 | ||
| Ulcerative colitis | Q84851901 | ||
| P275 | copyright license | Creative Commons CC0 License | Q6938433 |
| P6216 | copyright status | copyrighted, dedicated to the public domain by copyright holder | Q88088423 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cannabinoid receptor | Q421237 |
| cannabinoids | Q422936 | ||
| CNR2 | Q17907844 | ||
| P304 | page(s) | e109115 | |
| P577 | publication date | 2014-10-02 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Cannabinoids alleviate experimentally induced intestinal inflammation by acting at central and peripheral receptors | |
| P478 | volume | 9 |
| Q55019713 | A reliable and validated LC-MS/MS method for the simultaneous quantification of 4 cannabinoids in 40 consumer products. |
| Q35484505 | AM841, a covalent cannabinoid ligand, powerfully slows gastrointestinal motility in normal and stressed mice in a peripherally restricted manner |
| Q90312722 | Can We Target Endogenous Anti-inflammatory Responses as a Therapeutic Strategy for Inflammatory Bowel Disease? |
| Q49579501 | Cannabinoid Receptor-2 Ameliorates Inflammation in Murine Model of Crohn's Disease |
| Q26783956 | Cannabinoid-based drugs targeting CB1 and TRPV1, the sympathetic nervous system, and arthritis |
| Q92401471 | Cannabinoids and Opioids in the Treatment of Inflammatory Bowel Diseases |
| Q36157657 | Cannabinoids and Tremor Induced by Motor-related Disorders: Friend or Foe? |
| Q38918638 | Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go? |
| Q93002580 | Cannabis, Cannabinoids, and the Endocannabinoid System-Is there Therapeutic Potential for Inflammatory Bowel Disease? |
| Q35572176 | Endocannabinoid signaling at the periphery: 50 years after THC. |
| Q88924595 | Endocannabinoids in Body Weight Control |
| Q38593120 | Genetic Manipulation of the Endocannabinoid System |
| Q52762339 | Highly selective CB2 receptor agonist A836339 has gastroprotective effect on experimentally induced gastric ulcers in mice. |
| Q37032490 | In vitro and non-invasive in vivo effects of the cannabinoid-1 receptor agonist AM841 on gastrointestinal motor function in the rat. |
| Q39025067 | Manipulation of the Endocannabinoid System in Colitis: A Comprehensive Review |
| Q30842363 | Mapping Cannabinoid 1 Receptor Allosteric Site(s): Critical Molecular Determinant and Signaling Profile of GAT100, a Novel, Potent, and Irreversibly Binding Probe |
| Q36720905 | Molecular-interaction and signaling profiles of AM3677, a novel covalent agonist selective for the cannabinoid 1 receptor |
| Q26782927 | Neuroimmune pharmacological approaches |
| Q34500324 | Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s). |
| Q38815860 | Recent discoveries on absorption of dietary fat: Presence, synthesis, and metabolism of cytoplasmic lipid droplets within enterocytes |
| Q85890359 | Response to Utomo et al |
| Q30357558 | Role of Cannabinoids in Gastrointestinal Mucosal Defense and Inflammation |
| Q38822341 | The Role of the Endocannabinoid System in the Brain-Gut Axis |
| Q41821312 | The synthetic cannabinoid WIN55,212-2 mesylate decreases the production of inflammatory mediators in rheumatoid arthritis synovial fibroblasts by activating CB2, TRPV1, TRPA1 and yet unidentified receptor targets |
Search more.